Calamos Advisors
PTGX icon

Calamos Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Calamos Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.46M Sell
11,931
-11,542
-49% -$1.21M ﹤0.01% 703
2026
Q1 		$2.47M Buy
+23,473
New +$2.08M 0.01% 642

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Calamos Advisors's PTGX Position: Q2 2026 in Review

Calamos Advisors reduced its Protagonist Therapeutics (PTGX) stake by 49% in Q2 2026, selling an estimated $1.21M and leaving 11,931 shares worth $1.46M. The position accounts for ﹤0.01% of the portfolio, ranked #703.

Calamos Advisors first reported a position in PTGX in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.47M in Q1 2026. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Calamos Advisors held 11,931 shares of Protagonist Therapeutics worth $1.46M as of Q2 2026.
  • Calamos Advisors sold 11,542 Protagonist Therapeutics shares in Q2 2026, an estimated $1.21M.
  • Protagonist Therapeutics made up ﹤0.01% of Calamos Advisors's portfolio in Q2 2026, its #703 holding.
  • Calamos Advisors first reported a position in Protagonist Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Calamos Advisors's Protagonist Therapeutics position peaked at $2.47M in Q1 2026.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.